Investment in Bien, a Global Cannabis Lifestyle Brand
Intellectual property and brand
Bien is currently focused on exploiting the intellectual property ("IP") for its formulation and brand of soluble, odourless and flavourless "micro-dosed" CBD and THC powders that can be added to any beverage or food by a consumer.
Current business model and initial target market
Bien is preparing to license its IP and brand to manufacturers and distributors. Final testing of Bien's formulation is underway. On completion of the product testing, the initial market for launch of the Bien-branded products will be California. Manufacturing and distribution of the products to between 30 to 50 dispensaries, under license from Bien, is expected to commence in the second half of this year. MMJ notes that Bien's business model precludes handling the cannabis plant and/or seeking state licensing, to avoid status as a cannabis company. Bien is merely a branding/licensing company to the cannabis industry and its chain of custody is structured such that it never takes physical possession of the inventory.
Future business model and target market
Bien aims to expand by building its own manufacturing, distribution and marketing business, subject to obtaining appropriate licenses, in Canada from mid-2019 once cannabis edibles are legalised in that country.
Experienced management team
Bien's experienced management team is led by Zack Lister, founder and former CEO of Well Juicery, Canada's largest cold-pressed juice company.
MMJ has acquired 2.8 million common shares in Bien at CAD$0.25 per share. Each common share has a warrant exercisable at MMJ's discretion and convertible into one common share in Bien at CAD$0.35 per common share for a period of up to 36 months.
About MMJ PhytoTech Ltd
In October 2017, MMJ PhytoTech Limited (ASX:MMJ) announced its strategy to become an incubator for strategic investments across regulated jurisdictions globally covering the entire cannabis value chain.
Following the successful listing of United Greeneries Holdings Ltd ("United Greeneries") and Satipharm AG ("Satipharm") on the TSX-V through Harvest One Cannabis Inc. (CVE:HVT), MMJ has focused on the identification of a number of independent strategic investment opportunities that have the potential to deliver significant value to the Company's shareholders.
MMJ is actively pursuing early stage opportunities with the ability to deliver significant future revenue and the opportunity to provide dramatic global synergistic value as regulatory frameworks in key international markets continue to evolve. MMJ is targeting the full range of emerging cannabis-related sectors including healthcare products, technology, infrastructure, logistics, processing, cultivation, equipment, R&D, hemp food products and retail.
MMJ currently holds an equity stake of 53,333,333 shares in Harvest One, 100% ownership of Israeli-based R&D division PhytoTech Therapeutics Limited ("PTL") and strategic holdings in e-Sense Lab Limited (ASX:ESE) and private Canadian-based company WeedMe Inc.
MMJ PhytoTech Ltd